Oruka Therapeutics to Be Added to the Nasdaq Biotechnology Index (NBI)
Oruka Therapeutics to Be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the "NBI"). Oruka's addition will become effective prior to market open on Monday, December 23rd, 2024.
加利福尼亚州门罗公园，2024年12月18日（全球新闻网络）-- Oruka Therapeutics, Inc.（“Oruka”）（纳斯达克：ORKA），是一家开发新型生物制品的生物技术公司，旨在为包括斑块性银屑病在内的慢性皮肤疾病的治疗设定新的标准。今天宣布，Oruka预计将被纳入纳斯达克生物技术指数（纳斯达克：NBI）（“NBI”）。Oruka的加入将在2024年12月23日（星期一）市场开盘前生效。
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.
NBI旨在跟踪在纳斯达克证券市场上市的证券的表现，这些证券由根据行业分类基准分类为生物技术或药品公司的公司发行。NBI中的公司必须满足某些资格要求，包括但不限于最低市值、平均每日成交量和作为上市公司的调味品。NBI每年在12月进行评估，并根据修改的市值加权方法进行计算。
For more information about the NBI, visit:
有关NBI的更多信息，请访问：
About Oruka Therapeutics
关于Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
投资者联系：
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
译文内容由第三方软件翻译。